Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes, and Metabolism at The University of Florida at Gainesville (2011-present). He received his medical degree and did his internal medicine residency in Buenos Aires, Argentina. He completed a fellowship in Endocrinology, Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas. He moved to San Antonio, Texas (1992) and early-on worked on the mechanisms that lead to the development of type 2 diabetes mellitus (T2DM), as well as on complications associated with T2DM. He later focused on the relationship and underlying mechanisms of nonalcoholic fatty liver disease (NAFLD) in T2DM and its impact on dyslipidemia, diabetes control and cardiovascular disease. He also participated in several trials of intensive insulin therapy in type 2 diabetes and published several key studies on the subject. Dr. Cusi has also contributed to the understanding of the underlying mechanisms of NAFLD in obesity and diabetes, and published the first RCT on pioglitazone for NASH (Belfort et al, NEJM 2006). This was followed recently by a long-term study confirming its value for patients with prediabetes or T2DM and NASH (Cusi et al, Annals Intern Med 2016). Dr. Cusi’s current work centers on discovering the role of insulin resistance in type 2 diabetes and fatty liver disease, and the search for novel therapeutic agents and better ways to treat diabetes with oral agents or insulin in this setting.